BioXcel Therapeutics (NASDAQ:BTAI) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.
This table compares BioXcel Therapeutics and Aptorum Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
16.1% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Aptorum Group shares are held by institutional investors. 64.8% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares BioXcel Therapeutics and Aptorum Group’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioXcel Therapeutics||N/A||N/A||-$19.27 million||($1.32)||-8.26|
|Aptorum Group||$380,000.00||1,706.87||-$14.83 million||N/A||N/A|
Aptorum Group has higher revenue and earnings than BioXcel Therapeutics.
This is a breakdown of recent ratings and recommmendations for BioXcel Therapeutics and Aptorum Group, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioXcel Therapeutics currently has a consensus target price of $23.00, suggesting a potential upside of 111.01%. Aptorum Group has a consensus target price of $22.00, suggesting a potential downside of 1.87%. Given BioXcel Therapeutics’ higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Aptorum Group.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Aptorum Group Company Profile
Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs. It focuses on developing various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The company also focuses on the development of surgical robotics and medical devices; and operating outpatient clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in Central, Hong Kong.
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.